Combined inhibition of de novo glutathione and nucleotide biosynthesis is synthetically lethal in glioblastoma
Cell Reports · 2025-05 · 44 (5) · 115596
DOI: 10.1016/j.celrep.2025.115596 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2025-05. Verfasst von Suresh Udutha und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Glioblastoma, Glutathione, Nucleotides, Brain Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
Understanding the mechanisms by which oncogenic events alter metabolism will help identify metabolic weaknesses that can be targeted for therapy. Telomerase reverse transcriptase (TERT) is essential for telomere maintenance in most cancers. Here, we show that TERT acts via the transcription factor forkhead box O1 (FOXO1) to upregulate glutamate-cysteine ligase (GCLC), the rate-limiting enzyme for de novo biosynthesis of glutathione (GSH, reduced) in multiple cancer models, including glioblastoma (GBM). Genetic ablation of GCLC or pharmacological inhibition using buthionine sulfoximine (BSO) reduces GSH synthesis from [U-13C]-glutamine in GBMs. However, GCLC inhibition drives de novo pyrimidine nucleotide biosynthesis by upregulating the glutamine-utilizing enzymes glutaminase (GLS) and carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotatase (CAD) in an MYC-driven manner. Combining BSO with the glutamine antagonist JHU-083 is synthetically lethal in vitro and in vivo and significantly extends the survival of mice bearing intracranial GBM xenografts. Collectively, our studies advance our understanding of oncogene-induced metabolic vulnerabilities in GBMs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA; Crump Institute for Molecular Imaging, Los Angeles, CA, USA; UCLA Metabolomics Center, Los Angeles, CA, USA.
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA. Electronic address: pavithra.viswanath@ucsf.edu.
Förderung
- NCI NIH HHS
- National Institutes of Health National Cancer Institute
Zitieren
APA
Udutha, S., Taglang, C., Batsios, G., Gillespie, A. M., Tran, M., Hoeve, J. T., Graeber, T. G., & Viswanath, P. (2025). Combined inhibition of de novo glutathione and nucleotide biosynthesis is synthetically lethal in glioblastoma. Cell Reports, 44(5), 115596. https://doi.org/10.1016/j.celrep.2025.115596
Vancouver
Udutha S, Taglang C, Batsios G, Gillespie AM, Tran M, Hoeve JT, et al. Combined inhibition of de novo glutathione and nucleotide biosynthesis is synthetically lethal in glioblastoma. Cell Reports. 2025;44(5):115596. doi:10.1016/j.celrep.2025.115596
BibTeX
@article{Udutha2025,
author = {Udutha, Suresh and Taglang, Céline and Batsios, Georgios and Gillespie, Anne Marie and Tran, Meryssa and Hoeve, Johanna Ten and Graeber, Thomas G and Viswanath, Pavithra},
title = {Combined inhibition of de novo glutathione and nucleotide biosynthesis is synthetically lethal in glioblastoma},
journal = {Cell Reports},
year = {2025},
volume = {44},
number = {5},
pages = {115596},
doi = {10.1016/j.celrep.2025.115596}
}
EUVIMED